阿伐那非
(99%) 
中文名稱:    阿伐那非
中文同義詞:    4-[(3-氯-4-甲氧基芐基)氨基]-2-[2-(羥甲基)-1-吡咯烷基]-N-(2-嘧啶基甲基)-5-嘧啶甲磺酰胺;阿伐那非;阿瓦那非;阿伐那非.阿伐那菲;阿伐那非,4-[(3-氯-4-甲氧基芐基)氨基]-2-[2-(羥甲基)-1-吡咯烷基]-N-(2-嘧啶基甲基)-5-嘧啶甲磺酰胺
英文名稱:    Avanafil
英文同義詞:    (S)-2-(2-Hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[(2-pyrimidinylmethyl)carbamoyl]pyrimidine;4-[(3-Chloro-4-methoxybenzyl)amino]-2-[2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)-5-pyrimidinecarboxamide;Avanafil;Avanafil (usan/inn);D03217;4-[[(3-Chloro-4-Methoxyphenyl)Methyl] aMino]-2-[(2S)-2-(hydroxyMethyl)-1-pyrrolidinyl]-N-(2-pyriMidinylMethyl)-5-pyriMidinecarboxaMide;4-((3-chloro-4-Methoxybenzyl)aMino)-2-(2-(hydroxyMethyl)pyrrolidin-1-yl)-N-(pyriMidin-2-ylMethyl)pyriMidine-5-carboxaMide;(S)-4-((3-Chloro-4-Methoxybenzyl)aMino)-2-(2-(hydroxyMethyl)pyrrolidin-1-yl)-N-(pyriMidin-2-ylMethyl)pyriMidine-5-carboxaMide
CAS號(hào):    330784-47-9
分子式:    C23H26ClN7O3
分子量:    483.95
EINECS號(hào):    
相關(guān)類別:    Aromatics;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;活性分子;Inhibitor;原料藥;Avanafil;阿伐那非;醫(yī)藥原料;小分子抑制劑;Inhibitors;小分子抑制劑，天然產(chǎn)物;醫(yī)藥
Avanafil is a PDE5 inhibitor approved for erectile dysfunction by the FDA on April 27, 2012 and by EMA on June 21, 2013. Avanafil is known by the trademark names Stendra and Spedra and was developed by Vivus Inc. In July 2013 Vivus announced partnership with Menarini Group, which will commercialise and promote Spedra in over 40 European countries plus Australia and New Zealand. Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme which is found in various body tissues, but primarily in the corpus cavernosum penis, as well as the retina. Other similar drugs are sildenafil, tadalafil and vardenafil. The advantage of avanafil is that it has very fast onset of action compared with other PDE5 inhibitors. It is absorbed quickly, reaching a maximum concentration in about 30-45 minutes. About two-thirds of the participants were able to engage in sexual activity within 15 minutes.